Sutro Biopharma (STRO) EBITDA (2017 - 2026)

Sutro Biopharma has reported EBITDA for 9 years, with the latest figure at -$38.0 million in Q4 2025.

• Quarterly EBITDA rose 41.69% year-over-year to -$38.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$158.4 million (up 33.59% YoY) and the FY2025 annual result came in at -$158.4 million, up 33.59% from the prior year.
• EBITDA advanced to -$38.0 million in Q4 2025 per STRO's latest filing, from -$48.5 million in the prior quarter.
• Over five years, EBITDA peaked at $43.2 million in Q4 2023 and troughed at -$68.5 million in Q1 2025.
• A 5-year average of -$35.7 million and a median of -$40.7 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 187.67% in 2023, then sank 251.23% in 2024.
• Over 5 years, EBITDA stood at -$35.0 million in 2021, then tumbled by 40.49% to -$49.2 million in 2022, then soared by 187.67% to $43.2 million in 2023, then tumbled by 251.23% to -$65.3 million in 2024, then surged by 41.69% to -$38.0 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$38.0 million, -$48.5 million, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.